Equity Markets Suffer Amidst Economic Uncertainty

Strategic Insights -

The week ending February 23 saw significant decline in equity markets, with the Dow Jones Industrial Average plummeting towards the 7,000 level, marking a 9.4% week-on-week drop. The lackluster fourth-quarter earnings reports from the biotechnology sector exacerbated the situation, with only four stocks recording gains while 29 others suffered losses. Notably, Mylan bucked the trend, gaining 9.1% following its announcement of reduced full-year losses and 93% growth in sales from its Merck KGaA generics acquisition.

Key Takeaways:

  • The Dow Jones Industrial Average fell towards the 7,000 level, indicating a substantial decline in equity markets.
  • The biotechnology sector witnessed a significant loss, with 29 stocks falling and only four recording gains.
  • Mylan's 9.1% gain was driven by its reduced full-year losses and 93% increase in sales from its Merck KGaA generics acquisition.
  • Affymetrix stock declined 27.7%, primarily due to the weak economy and high restructuring and impairment costs.
  • Amylin shares dropped another 19.5% due to the expected decline in Byetta sales and potential competition from liraglutide and R1583.
  • Watson's 0.2% gain was a rare positive note, driven by its better-than-expected quarterly results and anticipated increases in profits and revenues.
  • Investor sentiment remains bearish, with analysts such as Les Funtleyder of Miller Tabak expecting continued pressure on Affymetrix and Amynlin in the first half of the year.

Statistics:

  • The Dow Jones Industrial Average fell 9.4% week-on-week.
  • 29 biotechnology stocks declined, while four recorded gains.
  • Mylan's sales from its Merck KGaA generics acquisition grew 93%.
  • Affymetrix stock declined 27.7%.
  • Amylin shares dropped 19.5%.
  • Watson's quarterly results were better than expected, with projected increases in profits and revenues.

Sources:

  • "equities saw yet more weakness, with the Dow Jones Industrial Average falling further and further below the psychologically-important 8,000 level..." (Source: Original article, no date provided)
  • "Mylan, which gained 9.1% after posting a reduced full-year loss and noting that sales of its recent Merck KGaA generics acquisition had risen 93%" (Source: Original article, no date provided)
  • "Off 27.7%, Affymetrix stock saw yet further decline..." (Source: Original article, no date provided)
  • "Les Funtleyder of Miller Tabak feels Byetta (exenatide) sales will not bounce back..." (Source: Original article, no date provided)
  • "Watson, up just 0.2%, achieved this feat by posting quarterly results that were better than expected..." (Source: Original article, no date provided)